| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 39 | 2023 | 469 | 7.560 |
Why?
|
| Prostatic Neoplasms | 64 | 2024 | 5996 | 4.510 |
Why?
|
| Abiraterone Acetate | 14 | 2023 | 89 | 4.350 |
Why?
|
| Androgen Antagonists | 21 | 2023 | 433 | 3.020 |
Why?
|
| Prednisone | 15 | 2023 | 1036 | 2.170 |
Why?
|
| Phenylthiohydantoin | 12 | 2023 | 106 | 2.080 |
Why?
|
| Receptors, Androgen | 16 | 2023 | 909 | 1.810 |
Why?
|
| Prostate-Specific Antigen | 19 | 2023 | 1039 | 1.720 |
Why?
|
| Thiohydantoins | 2 | 2021 | 27 | 1.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 42 | 2024 | 16612 | 1.360 |
Why?
|
| Bone Neoplasms | 18 | 2021 | 2669 | 1.290 |
Why?
|
| Androgen Receptor Antagonists | 6 | 2023 | 109 | 1.150 |
Why?
|
| Peritoneal Neoplasms | 7 | 2016 | 857 | 1.040 |
Why?
|
| Hedgehog Proteins | 4 | 2012 | 441 | 1.040 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 6 | 2016 | 38 | 1.020 |
Why?
|
| Prostatectomy | 11 | 2021 | 1006 | 0.970 |
Why?
|
| Taxoids | 14 | 2019 | 1010 | 0.900 |
Why?
|
| Male | 128 | 2024 | 129088 | 0.890 |
Why?
|
| Antineoplastic Agents | 31 | 2023 | 14653 | 0.880 |
Why?
|
| Kallikreins | 3 | 2021 | 86 | 0.830 |
Why?
|
| Androstenes | 8 | 2021 | 44 | 0.770 |
Why?
|
| Orchiectomy | 9 | 2015 | 226 | 0.750 |
Why?
|
| Nitriles | 13 | 2023 | 945 | 0.730 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 3 | 2016 | 181 | 0.710 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2019 | 178 | 0.700 |
Why?
|
| Social Media | 1 | 2024 | 211 | 0.700 |
Why?
|
| Adenocarcinoma | 12 | 2020 | 7976 | 0.670 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 430 | 0.670 |
Why?
|
| Biomarkers, Tumor | 18 | 2020 | 10750 | 0.660 |
Why?
|
| Humans | 156 | 2024 | 272087 | 0.640 |
Why?
|
| Aged | 81 | 2024 | 73517 | 0.620 |
Why?
|
| Androstenols | 3 | 2011 | 10 | 0.600 |
Why?
|
| Naphthalenes | 3 | 2016 | 84 | 0.590 |
Why?
|
| Benzamides | 10 | 2022 | 1882 | 0.590 |
Why?
|
| Anilides | 3 | 2020 | 296 | 0.590 |
Why?
|
| Thalidomide | 5 | 2010 | 595 | 0.570 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2016 | 510 | 0.570 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2022 | 10365 | 0.540 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2024 | 1011 | 0.540 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2014 | 128 | 0.520 |
Why?
|
| Neoplasm Metastasis | 18 | 2024 | 5330 | 0.500 |
Why?
|
| Aged, 80 and over | 39 | 2024 | 31066 | 0.500 |
Why?
|
| International Cooperation | 2 | 2016 | 327 | 0.500 |
Why?
|
| Urinary Bladder Neoplasms | 8 | 2024 | 2446 | 0.480 |
Why?
|
| Signal Transduction | 13 | 2023 | 12223 | 0.480 |
Why?
|
| Triazoles | 2 | 2016 | 629 | 0.440 |
Why?
|
| Middle Aged | 71 | 2024 | 90460 | 0.440 |
Why?
|
| Androgens | 8 | 2023 | 553 | 0.440 |
Why?
|
| Trench Fever | 1 | 2012 | 2 | 0.430 |
Why?
|
| Ovarian Neoplasms | 17 | 2014 | 4797 | 0.430 |
Why?
|
| Osteogenesis | 2 | 2012 | 271 | 0.420 |
Why?
|
| Pyridines | 3 | 2020 | 1312 | 0.420 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2023 | 5421 | 0.420 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2023 | 211 | 0.420 |
Why?
|
| Tumor Microenvironment | 6 | 2022 | 3026 | 0.420 |
Why?
|
| Carcinoma | 4 | 2014 | 2623 | 0.410 |
Why?
|
| Antineoplastic Agents, Hormonal | 9 | 2015 | 848 | 0.400 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 1020 | 0.400 |
Why?
|
| Prostate | 6 | 2023 | 1138 | 0.400 |
Why?
|
| Neoplasm Transplantation | 6 | 2021 | 1566 | 0.390 |
Why?
|
| Endocarditis, Bacterial | 1 | 2012 | 152 | 0.380 |
Why?
|
| Patient Readmission | 1 | 2016 | 592 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2020 | 3929 | 0.380 |
Why?
|
| Autocrine Communication | 1 | 2011 | 93 | 0.370 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2012 | 147 | 0.370 |
Why?
|
| Treatment Outcome | 37 | 2023 | 33909 | 0.370 |
Why?
|
| Extracellular Vesicles | 2 | 2023 | 135 | 0.360 |
Why?
|
| Testicular Neoplasms | 3 | 2013 | 555 | 0.350 |
Why?
|
| Neutropenia | 7 | 2019 | 1001 | 0.350 |
Why?
|
| Disease Progression | 22 | 2022 | 6911 | 0.340 |
Why?
|
| Prospective Studies | 16 | 2022 | 13410 | 0.330 |
Why?
|
| Combined Modality Therapy | 16 | 2024 | 9046 | 0.330 |
Why?
|
| Hyperthermia, Induced | 4 | 2015 | 510 | 0.330 |
Why?
|
| Adult | 51 | 2022 | 81933 | 0.320 |
Why?
|
| Double-Blind Method | 10 | 2021 | 2621 | 0.310 |
Why?
|
| Drug Administration Schedule | 9 | 2021 | 3543 | 0.300 |
Why?
|
| Registries | 1 | 2016 | 2253 | 0.290 |
Why?
|
| B7 Antigens | 2 | 2019 | 84 | 0.290 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2011 | 621 | 0.290 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2014 | 353 | 0.290 |
Why?
|
| Androstadienes | 3 | 2012 | 172 | 0.290 |
Why?
|
| Carboplatin | 9 | 2019 | 879 | 0.280 |
Why?
|
| Mice, SCID | 7 | 2019 | 1851 | 0.280 |
Why?
|
| Disease-Free Survival | 13 | 2021 | 10259 | 0.270 |
Why?
|
| Survival Analysis | 18 | 2023 | 9326 | 0.260 |
Why?
|
| Cell Line, Tumor | 14 | 2023 | 14881 | 0.260 |
Why?
|
| Testosterone | 4 | 2023 | 735 | 0.260 |
Why?
|
| Survival Rate | 15 | 2024 | 12534 | 0.260 |
Why?
|
| Dehydroepiandrosterone | 2 | 2016 | 34 | 0.260 |
Why?
|
| Bone Density Conservation Agents | 3 | 2015 | 205 | 0.240 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 15279 | 0.240 |
Why?
|
| BRCA1 Protein | 3 | 2023 | 522 | 0.240 |
Why?
|
| Cisplatin | 11 | 2022 | 2497 | 0.240 |
Why?
|
| Tissue Array Analysis | 5 | 2017 | 760 | 0.240 |
Why?
|
| Linguistics | 1 | 2024 | 26 | 0.240 |
Why?
|
| Cadherins | 3 | 2015 | 676 | 0.230 |
Why?
|
| BRCA2 Protein | 2 | 2023 | 379 | 0.230 |
Why?
|
| Castration | 3 | 2014 | 126 | 0.230 |
Why?
|
| Mice | 21 | 2023 | 36053 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2023 | 320 | 0.220 |
Why?
|
| Natural Language Processing | 1 | 2024 | 119 | 0.220 |
Why?
|
| Recombinational DNA Repair | 1 | 2023 | 78 | 0.210 |
Why?
|
| Animals | 24 | 2023 | 62822 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 6 | 2022 | 5213 | 0.210 |
Why?
|
| Time Factors | 11 | 2021 | 13139 | 0.210 |
Why?
|
| Epithelial Cells | 2 | 2007 | 1892 | 0.210 |
Why?
|
| Folic Acid Antagonists | 1 | 2022 | 48 | 0.200 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2021 | 2 | 0.200 |
Why?
|
| Radium | 2 | 2021 | 97 | 0.200 |
Why?
|
| Perception | 1 | 2024 | 351 | 0.200 |
Why?
|
| Ketone Bodies | 1 | 2021 | 57 | 0.200 |
Why?
|
| Nausea | 2 | 2016 | 540 | 0.200 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 3856 | 0.200 |
Why?
|
| Urethral Neoplasms | 1 | 2022 | 64 | 0.200 |
Why?
|
| Gene Expression | 2 | 2021 | 3690 | 0.200 |
Why?
|
| Health Services for the Aged | 2 | 2019 | 52 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 6270 | 0.190 |
Why?
|
| Retrospective Studies | 23 | 2024 | 39831 | 0.190 |
Why?
|
| Seminoma | 2 | 2013 | 88 | 0.190 |
Why?
|
| Health Policy | 1 | 2024 | 281 | 0.190 |
Why?
|
| Heterografts | 3 | 2019 | 745 | 0.190 |
Why?
|
| Fatigue | 4 | 2019 | 1281 | 0.190 |
Why?
|
| Cyclobutanes | 1 | 2021 | 36 | 0.190 |
Why?
|
| Neoplasm Staging | 16 | 2022 | 13993 | 0.190 |
Why?
|
| Carboxylic Acids | 1 | 2021 | 58 | 0.180 |
Why?
|
| Prognosis | 14 | 2023 | 22555 | 0.180 |
Why?
|
| Precision Medicine | 2 | 2020 | 1207 | 0.180 |
Why?
|
| Drug Discovery | 3 | 2019 | 331 | 0.180 |
Why?
|
| Finasteride | 2 | 2021 | 33 | 0.180 |
Why?
|
| Bone Marrow | 3 | 2014 | 2446 | 0.180 |
Why?
|
| Estrogen Receptor beta | 1 | 2021 | 167 | 0.180 |
Why?
|
| Prostatic Hyperplasia | 1 | 2021 | 222 | 0.170 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 293 | 0.170 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 220 | 0.170 |
Why?
|
| Genes, BRCA1 | 4 | 2003 | 398 | 0.170 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 872 | 0.170 |
Why?
|
| Neoplasm Proteins | 4 | 2015 | 3363 | 0.160 |
Why?
|
| Transplantation, Heterologous | 5 | 2012 | 1086 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 9101 | 0.160 |
Why?
|
| Drug Combinations | 2 | 2019 | 637 | 0.160 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2014 | 522 | 0.160 |
Why?
|
| Heart Failure | 1 | 2012 | 2500 | 0.160 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 562 | 0.160 |
Why?
|
| Geriatrics | 1 | 2019 | 90 | 0.160 |
Why?
|
| Random Allocation | 1 | 2020 | 746 | 0.160 |
Why?
|
| Dasatinib | 2 | 2020 | 881 | 0.160 |
Why?
|
| Paclitaxel | 7 | 2007 | 2099 | 0.160 |
Why?
|
| Kidney Neoplasms | 3 | 2023 | 3153 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2019 | 349 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 1388 | 0.150 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2014 | 636 | 0.150 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 2 | 2015 | 10 | 0.150 |
Why?
|
| Risk Assessment | 5 | 2019 | 6885 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 5118 | 0.150 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 133 | 0.150 |
Why?
|
| Fractures, Spontaneous | 2 | 2015 | 87 | 0.150 |
Why?
|
| Deoxycytidine | 5 | 2006 | 1378 | 0.140 |
Why?
|
| Lactic Acid | 1 | 2019 | 312 | 0.140 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 320 | 0.140 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2019 | 172 | 0.140 |
Why?
|
| Vaccines | 1 | 2022 | 396 | 0.140 |
Why?
|
| Multiple Myeloma | 4 | 2010 | 2287 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2015 | 189 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 630 | 0.140 |
Why?
|
| ROC Curve | 1 | 2020 | 1248 | 0.140 |
Why?
|
| Antigens, Neoplasm | 2 | 2015 | 1590 | 0.130 |
Why?
|
| Biopsy | 4 | 2021 | 3544 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 2400 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 609 | 0.130 |
Why?
|
| Integrin alpha5 | 1 | 2015 | 13 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 3 | 2019 | 1599 | 0.130 |
Why?
|
| Cystectomy | 4 | 2022 | 632 | 0.130 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 26 | 0.130 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 1 | 2015 | 14 | 0.130 |
Why?
|
| Biomarkers | 3 | 2023 | 5115 | 0.130 |
Why?
|
| Introns | 2 | 2015 | 461 | 0.130 |
Why?
|
| Bridged-Ring Compounds | 1 | 2016 | 180 | 0.130 |
Why?
|
| Female | 42 | 2024 | 149288 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 1338 | 0.130 |
Why?
|
| Caveolin 1 | 1 | 2016 | 206 | 0.120 |
Why?
|
| Hydrocortisone | 1 | 2016 | 406 | 0.120 |
Why?
|
| beta-Thalassemia | 1 | 2015 | 33 | 0.120 |
Why?
|
| Neoplasm Grading | 5 | 2021 | 1827 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 514 | 0.120 |
Why?
|
| Immunotherapy | 3 | 2024 | 3546 | 0.120 |
Why?
|
| Disease Models, Animal | 7 | 2019 | 7476 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 152 | 0.120 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2014 | 41 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2011 | 895 | 0.120 |
Why?
|
| Ki-67 Antigen | 2 | 2014 | 685 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 1905 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2014 | 51 | 0.120 |
Why?
|
| Dihydrotestosterone | 1 | 2014 | 116 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 237 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 271 | 0.110 |
Why?
|
| Vomiting | 1 | 2016 | 361 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 725 | 0.110 |
Why?
|
| Immunohistochemistry | 10 | 2019 | 7828 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2430 | 0.110 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 1443 | 0.110 |
Why?
|
| Cell Nucleus | 2 | 2021 | 1740 | 0.110 |
Why?
|
| Quinolones | 1 | 2014 | 163 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 5 | 2019 | 1323 | 0.110 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2013 | 50 | 0.110 |
Why?
|
| Thiophenes | 1 | 2014 | 148 | 0.110 |
Why?
|
| Infusions, Intravenous | 3 | 2011 | 1442 | 0.110 |
Why?
|
| Age Factors | 7 | 2021 | 5526 | 0.110 |
Why?
|
| Alopecia | 2 | 2005 | 124 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2019 | 1049 | 0.110 |
Why?
|
| Urea | 1 | 2014 | 306 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2022 | 1372 | 0.110 |
Why?
|
| Comorbidity | 1 | 2019 | 2439 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2007 | 609 | 0.100 |
Why?
|
| Lipids | 1 | 2016 | 661 | 0.100 |
Why?
|
| Remission Induction | 2 | 2011 | 3645 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2023 | 2417 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 428 | 0.100 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2014 | 165 | 0.100 |
Why?
|
| Imidazoles | 4 | 2015 | 1056 | 0.100 |
Why?
|
| Phthalazines | 1 | 2014 | 263 | 0.100 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2012 | 24 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2014 | 719 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2014 | 860 | 0.100 |
Why?
|
| Ossification, Heterotopic | 1 | 2012 | 70 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 390 | 0.100 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2014 | 243 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2012 | 105 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2014 | 442 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2014 | 829 | 0.090 |
Why?
|
| Quality of Life | 3 | 2023 | 4755 | 0.090 |
Why?
|
| Anemia, Sickle Cell | 1 | 2015 | 369 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2016 | 711 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 566 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2015 | 1436 | 0.090 |
Why?
|
| Dacarbazine | 2 | 2005 | 505 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2011 | 239 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1378 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2019 | 1464 | 0.090 |
Why?
|
| Viscera | 1 | 2010 | 92 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 721 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 4496 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1075 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 2681 | 0.090 |
Why?
|
| Integrins | 1 | 2011 | 278 | 0.080 |
Why?
|
| Prostaglandins | 1 | 2009 | 84 | 0.080 |
Why?
|
| Drug Therapy, Combination | 5 | 2020 | 2369 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 619 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2019 | 2761 | 0.080 |
Why?
|
| Mitosis | 1 | 2012 | 692 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2011 | 243 | 0.080 |
Why?
|
| Selenomethionine | 1 | 2009 | 40 | 0.080 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2003 | 285 | 0.080 |
Why?
|
| Celecoxib | 1 | 2009 | 203 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 2022 | 1469 | 0.080 |
Why?
|
| Peptides | 1 | 2015 | 1529 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2011 | 427 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2009 | 80 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 214 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 622 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2015 | 6987 | 0.080 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Diphosphonates | 2 | 2015 | 264 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2022 | 686 | 0.080 |
Why?
|
| Methotrexate | 2 | 2010 | 1033 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2009 | 203 | 0.080 |
Why?
|
| Kidney | 3 | 2015 | 2266 | 0.080 |
Why?
|
| RANK Ligand | 1 | 2009 | 116 | 0.080 |
Why?
|
| Life Tables | 2 | 2005 | 122 | 0.080 |
Why?
|
| Stromal Cells | 2 | 2014 | 835 | 0.080 |
Why?
|
| Autophagy | 1 | 2014 | 922 | 0.080 |
Why?
|
| beta Catenin | 1 | 2012 | 691 | 0.080 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4811 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 1483 | 0.070 |
Why?
|
| Anemia | 2 | 2019 | 730 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2010 | 668 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 498 | 0.070 |
Why?
|
| Consensus | 2 | 2022 | 1116 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2009 | 1074 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 372 | 0.070 |
Why?
|
| Pain Management | 1 | 2012 | 715 | 0.070 |
Why?
|
| Fever | 2 | 2010 | 516 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 139 | 0.070 |
Why?
|
| Salvage Therapy | 3 | 2021 | 2119 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 399 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2021 | 9500 | 0.070 |
Why?
|
| DNA Damage | 1 | 2014 | 1989 | 0.070 |
Why?
|
| Palliative Care | 3 | 2012 | 2161 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2009 | 1077 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 2359 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2016 | 1622 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4352 | 0.060 |
Why?
|
| Aza Compounds | 1 | 2005 | 24 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2472 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 4400 | 0.060 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 5187 | 0.060 |
Why?
|
| Neoplasms | 5 | 2022 | 15930 | 0.060 |
Why?
|
| Piperazines | 1 | 2014 | 2152 | 0.060 |
Why?
|
| Estramustine | 1 | 2005 | 30 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 300 | 0.060 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2004 | 38 | 0.060 |
Why?
|
| Melphalan | 1 | 2007 | 875 | 0.060 |
Why?
|
| Germinoma | 1 | 2004 | 84 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2014 | 4968 | 0.060 |
Why?
|
| Greece | 4 | 2006 | 27 | 0.060 |
Why?
|
| North America | 2 | 2015 | 341 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 518 | 0.060 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2020 | 693 | 0.060 |
Why?
|
| Models, Biological | 2 | 2010 | 3223 | 0.060 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2023 | 18 | 0.060 |
Why?
|
| Patient Selection | 1 | 2011 | 2045 | 0.060 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 134 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 3980 | 0.060 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2005 | 303 | 0.060 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2006 | 343 | 0.060 |
Why?
|
| Mifepristone | 1 | 2023 | 196 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 2035 | 0.050 |
Why?
|
| Europe | 2 | 2015 | 660 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 76 | 0.050 |
Why?
|
| Psoriasis | 1 | 2004 | 138 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2005 | 1913 | 0.050 |
Why?
|
| Cyclophosphamide | 3 | 2007 | 3231 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2007 | 1066 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 4071 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7958 | 0.050 |
Why?
|
| Quinolines | 1 | 2005 | 403 | 0.050 |
Why?
|
| Apoptosis | 5 | 2016 | 7837 | 0.050 |
Why?
|
| Hormones | 1 | 2023 | 293 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 3651 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2005 | 443 | 0.050 |
Why?
|
| Exons | 2 | 2002 | 1388 | 0.050 |
Why?
|
| Cell Plasticity | 1 | 2022 | 67 | 0.050 |
Why?
|
| Phytoestrogens | 1 | 2021 | 26 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2004 | 314 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 1615 | 0.050 |
Why?
|
| Carcinoma, Medullary | 1 | 2003 | 248 | 0.050 |
Why?
|
| Diagnostic Imaging | 2 | 2023 | 1178 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2021 | 2457 | 0.050 |
Why?
|
| Pain | 2 | 2011 | 1697 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 1085 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2005 | 607 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2009 | 1544 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5693 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2015 | 1470 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2022 | 327 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1592 | 0.040 |
Why?
|
| Scalp | 1 | 2002 | 155 | 0.040 |
Why?
|
| Hypothermia, Induced | 1 | 2002 | 177 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2002 | 321 | 0.040 |
Why?
|
| RNA Interference | 2 | 2015 | 1397 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 320 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2009 | 1919 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2022 | 6489 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 97 | 0.040 |
Why?
|
| Indazoles | 1 | 2022 | 310 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 422 | 0.040 |
Why?
|
| Receptors, Estrogen | 3 | 2021 | 2268 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 203 | 0.040 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 1556 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 4963 | 0.040 |
Why?
|
| Bone and Bones | 2 | 2014 | 613 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2015 | 1017 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2019 | 61 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 446 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2022 | 601 | 0.040 |
Why?
|
| Osteoblasts | 2 | 2014 | 394 | 0.040 |
Why?
|
| Dehydration | 1 | 2019 | 91 | 0.040 |
Why?
|
| Lung Neoplasms | 4 | 2006 | 12012 | 0.040 |
Why?
|
| Point Mutation | 1 | 2002 | 793 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1472 | 0.040 |
Why?
|
| Quinazolines | 1 | 2004 | 953 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2002 | 613 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 2322 | 0.040 |
Why?
|
| Proteoglycans | 2 | 2010 | 278 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 2006 | 4994 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2021 | 448 | 0.040 |
Why?
|
| Anorexia | 1 | 2019 | 147 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2023 | 4200 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 5804 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 253 | 0.040 |
Why?
|
| Vidarabine | 1 | 2003 | 1383 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2013 | 1433 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 1351 | 0.040 |
Why?
|
| Dexamethasone | 3 | 2010 | 1497 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2020 | 915 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 2219 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2002 | 1102 | 0.040 |
Why?
|
| Fatty Acid Synthase, Type I | 1 | 2016 | 12 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2016 | 54 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 1966 | 0.030 |
Why?
|
| Piperidines | 1 | 2022 | 1091 | 0.030 |
Why?
|
| ErbB Receptors | 2 | 2021 | 2383 | 0.030 |
Why?
|
| RNA | 1 | 2021 | 1072 | 0.030 |
Why?
|
| Young Adult | 2 | 2011 | 22142 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 1014 | 0.030 |
Why?
|
| Diarrhea | 1 | 2019 | 730 | 0.030 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 741 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 3704 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 113 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 70 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2019 | 555 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 125 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 879 | 0.030 |
Why?
|
| Denosumab | 1 | 2015 | 72 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2017 | 2975 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2017 | 423 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2015 | 75 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2015 | 125 | 0.030 |
Why?
|
| Toxoplasmosis | 1 | 2015 | 49 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 155 | 0.030 |
Why?
|
| Herpes Zoster | 1 | 2015 | 53 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2014 | 210 | 0.030 |
Why?
|
| Cell Proliferation | 3 | 2016 | 7302 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 1 | 2014 | 39 | 0.030 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2014 | 36 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 1143 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2015 | 177 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 262 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2014 | 89 | 0.030 |
Why?
|
| Proteinuria | 1 | 2015 | 166 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2021 | 802 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1742 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 182 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2014 | 53 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1439 | 0.030 |
Why?
|
| Cystitis | 1 | 2015 | 109 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2015 | 296 | 0.030 |
Why?
|
| DNA Repair | 1 | 2022 | 1912 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1015 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 566 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 554 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 909 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2003 | 16244 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 265 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2007 | 770 | 0.030 |
Why?
|
| Lung | 1 | 2004 | 3295 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2013 | 126 | 0.030 |
Why?
|
| Risk Factors | 3 | 2015 | 18051 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 272 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 2496 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 6783 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 591 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1607 | 0.030 |
Why?
|
| Hyaluronan Synthases | 1 | 2012 | 17 | 0.030 |
Why?
|
| Annexin A4 | 1 | 2011 | 8 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2013 | 371 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2014 | 293 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2011 | 15 | 0.030 |
Why?
|
| Integrin alpha4 | 1 | 2011 | 26 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2017 | 759 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2013 | 256 | 0.020 |
Why?
|
| Cathepsin B | 1 | 2011 | 35 | 0.020 |
Why?
|
| Centrosome | 1 | 2012 | 107 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2015 | 1718 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 621 | 0.020 |
Why?
|
| Ifosfamide | 2 | 2002 | 357 | 0.020 |
Why?
|
| Genomics | 1 | 2022 | 2830 | 0.020 |
Why?
|
| Peptide Library | 1 | 2011 | 165 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 5841 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 2012 | 168 | 0.020 |
Why?
|
| Etoposide | 2 | 2004 | 905 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 487 | 0.020 |
Why?
|
| Recurrence | 3 | 2006 | 4887 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2010 | 52 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 416 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 3395 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2290 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2015 | 973 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3078 | 0.020 |
Why?
|
| Adolescent | 3 | 2022 | 32730 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2010 | 153 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2010 | 90 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 2270 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2335 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2010 | 311 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 5107 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 5756 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 725 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 2035 | 0.020 |
Why?
|
| Ki-1 Antigen | 1 | 2010 | 186 | 0.020 |
Why?
|
| Microdissection | 1 | 2009 | 86 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 357 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 1057 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 898 | 0.020 |
Why?
|
| Glioma | 1 | 2000 | 1988 | 0.020 |
Why?
|
| Bacteremia | 1 | 2015 | 722 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3469 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2010 | 355 | 0.020 |
Why?
|
| Pedigree | 2 | 2003 | 2036 | 0.020 |
Why?
|
| Bortezomib | 1 | 2010 | 542 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 5566 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 3528 | 0.020 |
Why?
|
| Vancomycin | 1 | 2010 | 292 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 490 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 582 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 4371 | 0.020 |
Why?
|
| Laminin | 1 | 2008 | 214 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 1349 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 1212 | 0.020 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2007 | 75 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 546 | 0.020 |
Why?
|
| Melanoma | 1 | 2005 | 5592 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 250 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 5603 | 0.020 |
Why?
|
| Pyrazines | 1 | 2010 | 513 | 0.020 |
Why?
|
| Keratins | 1 | 2008 | 352 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 5248 | 0.020 |
Why?
|
| Vimentin | 1 | 2008 | 260 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 4984 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 318 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 1092 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 639 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2014 | 4360 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 1994 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 1064 | 0.020 |
Why?
|
| History, 18th Century | 1 | 2006 | 88 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2198 | 0.020 |
Why?
|
| Echoencephalography | 1 | 2006 | 27 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 1102 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 3646 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2010 | 1056 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2014 | 2139 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 212 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2010 | 2048 | 0.020 |
Why?
|
| Collagen | 1 | 2008 | 739 | 0.020 |
Why?
|
| Histamine H1 Antagonists | 1 | 2005 | 25 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2005 | 107 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2319 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1950 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2337 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2005 | 131 | 0.010 |
Why?
|
| Contraindications | 1 | 2004 | 155 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2005 | 183 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3947 | 0.010 |
Why?
|
| Mononeuropathies | 1 | 2004 | 2 | 0.010 |
Why?
|
| Terminally Ill | 1 | 2005 | 96 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2005 | 200 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3080 | 0.010 |
Why?
|
| Vinblastine | 1 | 2005 | 462 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2004 | 203 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 692 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 2804 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2010 | 2867 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 845 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 465 | 0.010 |
Why?
|
| Length of Stay | 1 | 2010 | 2015 | 0.010 |
Why?
|
| Bleomycin | 1 | 2004 | 482 | 0.010 |
Why?
|
| DNA | 1 | 2012 | 3089 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 499 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 2333 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 2355 | 0.010 |
Why?
|
| Disease Management | 1 | 2009 | 1113 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2004 | 255 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 192 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 729 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 3472 | 0.010 |
Why?
|
| CA-125 Antigen | 1 | 2004 | 228 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 3512 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 207 | 0.010 |
Why?
|
| Proteins | 1 | 2010 | 2058 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 3072 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 5196 | 0.010 |
Why?
|
| Mutation | 3 | 2012 | 15944 | 0.010 |
Why?
|
| Guanine | 1 | 2002 | 157 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 460 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1581 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2005 | 499 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2005 | 378 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2013 | 3664 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 5067 | 0.010 |
Why?
|
| Turkey | 1 | 2000 | 66 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 7237 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1209 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 381 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 879 | 0.010 |
Why?
|
| Child | 2 | 2015 | 30559 | 0.010 |
Why?
|
| Outpatients | 1 | 2002 | 469 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 2958 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2010 | 1950 | 0.010 |
Why?
|
| Adenine | 1 | 2002 | 669 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 6210 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 745 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 3176 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2004 | 1649 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 3132 | 0.010 |
Why?
|
| Rituximab | 1 | 2002 | 1588 | 0.010 |
Why?
|
| Sex Factors | 1 | 2002 | 2208 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 2365 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 3671 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 1265 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1842 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 2005 | 1389 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 5502 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 4195 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2002 | 1699 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 4900 | 0.010 |
Why?
|